Researchers from the U.K.’s University of Birmingham have filed for protection of an implantable device for targeted drug delivery in patients who have undergone surgery, particularly surgery to remove one or more tumors.

Eli Lilly and Co. continues its development of an oral drug delivery device that can successfully deliver a drug that would otherwise be ineffective when taken orally.

Watertown, Mass.-based Lyndra Therapeutics Inc. is seeking patent protection for gastric residence drug delivery systems with improved shelf lives through their inclusion of a metal core.

Ali Golshan, a practicing interventional radiologist, has been granted protection for a minimally invasive treatment for varicose veins.

In the first patenting from Chicago-based Novaxs Biotech Corp., its co-founders, Alina Rui Su and Jonathan Tianyi Xing, describe an injection system for needle-free, high-pressure drug delivery.

Since its founding by the National Institutes of Health (NIH), the scientists of the All of Us Research Program have set the goal to analyze the largest diversity of the genomic population in the country and end the under-representation of its different groups. The project has expanded the vision of several pathologies, discovered thousands of new genetic variants, redefined the risk genes for common diseases, and stratified them, uncovering eight different forms in the case of type 2 diabetes (T2D). Their results create a pathway for a new age of precision medicine.

Spyglass Ophthalmics Inc. is seeking patent protection for intraocular drug delivery devices and methods of delivering therapeutic agents to the eye. The methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the patient’s eye.

Researchers from the Institute for Bioengineering of Catalonia (IBEC) and collaborators have successfully treated bladder tumors in mice using urease-powered nanobots. The testing consisted of the administration of 18F-nanorobots to tumor-bearing mice divided into four groups depending on tumor volumes using a group of non-tumor-bearing mice as control. Importantly, the therapy remained in the bladder with only a very small proportion of radioactivity seen in other organs. The results were published in Nature Nanotechnology on Jan. 15, 2024.

Vaxess Technologies Inc. seeks patent protection for devices that enable the reliable application of silk fibroin-based microneedle medicament patches used for delivering small molecule drugs, vaccines, peptides, biologics, antibodies, hormones or other materials into or through the skin.

One of the largest med-tech deals of 2023 was wiped off the charts when Medtronic plc terminated a $738 million agreement to acquire South Korean wearable insulin patch maker Eoflow Co. Ltd., citing “multiple breaches” under its agreements, on Dec. 6.